Matinas BioPharma Holdings (MTNB) Asset Utilization Ratio (2015 - 2023)
Matinas BioPharma Holdings (MTNB) posted quarterly Asset Utilization Ratio of 0.04 for Q4 2023, down 42.17% year-over-year from 0.07 in Q4 2022, and down 40.99% quarter-over-quarter from 0.07 in Q3 2023.
Matinas BioPharma Holdings (MTNB) Asset Utilization Ratio (2015 - 2023) Analysis & Trends
Matinas BioPharma Holdings (MTNB) has reported Asset Utilization Ratio for 9 consecutive years, with 0.04 the latest figure, recorded in Q4 2023.
- In Q4 2023, Asset Utilization Ratio fell 42.17% year-over-year to 0.04; the TTM figure through Dec 2023 stood at 0.04 (down 42.17% YoY), while the FY2023 annual figure was 0.03, down 47.81% from the prior year.
- Asset Utilization Ratio eased to 0.04 in Q4 2023 per MTNB's latest filing, from 0.07 in the prior quarter.
- Across five years, Asset Utilization Ratio topped out at 0.09 in Q2 2023 and bottomed at 0.0 in Q3 2021.
- Historically, Asset Utilization Ratio has averaged 0.03 across 5 years, with a median of 0.0 in 2020.
- Annual changes were most pronounced in 2021 — Asset Utilization Ratio tumbled 117.86% — and 2022, when it surged 13323.09%.
- Matinas BioPharma Holdings' Asset Utilization Ratio stood at 0.0 in 2019, then plunged by 78.56% to 0.0 in 2020, then rose by 13.61% to 0.0 in 2021, then surged by 13323.09% to 0.07 in 2022, then plunged by 42.17% to 0.04 in 2023.
- Business Quant data shows MTNB's Asset Utilization Ratio at 0.04 in Q4 2023, 0.07 in Q3 2023, and 0.09 in Q2 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Asset Util. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.76 Bn | 131.91 Bn | 2.84 Bn | 0.47 |
| 2 | Regeneron Pharmaceuticals | 86.51 Bn | 78.51 Bn | 3.93 Bn | 0.38 |
| 3 | Argenx Se | 65.74 Bn | 60.56 Bn | 1.37 Bn | - |
| 4 | Moderna | 59.39 Bn | 54.26 Bn | 52.00 Mn | 0.20 |
| 5 | BeOne Medicines | 42.24 Bn | 37.15 Bn | 1.53 Bn | 0.69 |
| 6 | Alnylam Pharmaceuticals | 31.78 Bn | 28.47 Bn | 992.69 Mn | 0.90 |
| 7 | BioNTech SE | 28.65 Bn | 10.26 Bn | 668.28 Mn | 0.13 |
| 8 | Insmed | 27.58 Bn | 26.42 Bn | 358.27 Mn | 0.54 |
| 9 | Royalty Pharma | 27.22 Bn | 26.39 Bn | - | 0.13 |
| 10 | Matinas BioPharma Holdings | 1.21 Mn | 397,207.65 | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2023 | 0.04 |
| Sep 30, 2023 | 0.07 |
| Jun 30, 2023 | 0.09 |
| Mar 31, 2023 | 0.09 |
| Dec 31, 2022 | 0.07 |
| Sep 30, 2022 | 0.04 |
| Jun 30, 2022 | 0.02 |
| Dec 31, 2021 | 0.00 |
| Sep 30, 2021 | 0.00 |
| Jun 30, 2021 | 0.00 |
| Mar 31, 2021 | 0.00 |
| Dec 31, 2020 | 0.00 |
| Sep 30, 2020 | 0.00 |
| Dec 31, 2019 | 0.00 |
| Sep 30, 2019 | 0.00 |
| Jun 30, 2019 | 0.00 |
| Dec 31, 2018 | 0.01 |
| Sep 30, 2018 | 0.01 |
| Jun 30, 2018 | 0.02 |
| Mar 31, 2018 | 0.01 |